485 related articles for article (PubMed ID: 17050602)
1. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.
De Rose R; Batten CJ; Smith MZ; Fernandez CS; Peut V; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Venturi V; Davenport MP; Kent SJ
J Virol; 2007 Jan; 81(1):292-300. PubMed ID: 17050602
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus.
Dale CJ; De Rose R; Stratov I; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Kent SJ
J Virol; 2004 Dec; 78(24):13819-28. PubMed ID: 15564490
[TBL] [Abstract][Full Text] [Related]
3. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
Cox JH; Ferrari MG; Earl P; Lane JR; Jagodzinski LL; Polonis VR; Kuta EG; Boyer JD; Ratto-Kim S; Eller LA; Pham DT; Hart L; Montefiori D; Ferrari G; Parrish S; Weiner DB; Moss B; Kim JH; Birx D; VanCott TC
Vaccine; 2012 Feb; 30(10):1830-40. PubMed ID: 22234262
[TBL] [Abstract][Full Text] [Related]
4. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
5. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.
Ourmanov I; Brown CR; Moss B; Carroll M; Wyatt L; Pletneva L; Goldstein S; Venzon D; Hirsch VM
J Virol; 2000 Mar; 74(6):2740-51. PubMed ID: 10684290
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIV.
Almond N; Berry N; Stebbings R; Preston M; Ham C; Page M; Ferguson D; Rose N; Li B; Mee ET; Hassall M; Stahl-Hennig C; Athanasopoulos T; Papagatsias T; Herath S; Benlahrech A; Dickson G; Meiser A; Patterson S
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413132
[TBL] [Abstract][Full Text] [Related]
8. Mucosal and systemic SIV-specific cytotoxic CD4
Khanna M; Jackson RJ; Alcantara S; Amarasena TH; Li Z; Kelleher AD; Kent SJ; Ranasinghe C
Sci Rep; 2019 Apr; 9(1):5661. PubMed ID: 30952887
[TBL] [Abstract][Full Text] [Related]
9. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
Hel Z; Nacsa J; Tryniszewska E; Tsai WP; Parks RW; Montefiori DC; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
J Immunol; 2002 Nov; 169(9):4778-87. PubMed ID: 12391187
[TBL] [Abstract][Full Text] [Related]
10. Vector Order Determines Protection against Pathogenic Simian Immunodeficiency Virus Infection in a Triple-Component Vaccine by Balancing CD4
Sauermann U; Radaelli A; Stolte-Leeb N; Raue K; Bissa M; Zanotto C; Krawczak M; Tenbusch M; Überla K; Keele BF; De Giuli Morghen C; Sopper S; Stahl-Hennig C
J Virol; 2017 Dec; 91(23):. PubMed ID: 28904195
[TBL] [Abstract][Full Text] [Related]
11. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
[TBL] [Abstract][Full Text] [Related]
12. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M
J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693
[TBL] [Abstract][Full Text] [Related]
13. Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques.
Carnathan DG; Wetzel KS; Yu J; Lee ST; Johnson BA; Paiardini M; Yan J; Morrow MP; Sardesai NY; Weiner DB; Ertl HC; Silvestri G
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):518-23. PubMed ID: 25550504
[TBL] [Abstract][Full Text] [Related]
14. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
[TBL] [Abstract][Full Text] [Related]
15. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.
Doria-Rose NA; Ohlen C; Polacino P; Pierce CC; Hensel MT; Kuller L; Mulvania T; Anderson D; Greenberg PD; Hu SL; Haigwood NL
J Virol; 2003 Nov; 77(21):11563-77. PubMed ID: 14557642
[TBL] [Abstract][Full Text] [Related]
16. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
[TBL] [Abstract][Full Text] [Related]
17. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease.
Fultz PN; Stallworth J; Porter D; Novak M; Anderson MJ; Morrow CD
Virology; 2003 Oct; 315(2):425-37. PubMed ID: 14585346
[TBL] [Abstract][Full Text] [Related]
19. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
[TBL] [Abstract][Full Text] [Related]
20. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M
J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
